# US 2023/0058864 A1 · Compositions and methods for treating pathologic calcification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058864 A1
- Document ID: US20230058864A1
- Status: Published application
- Kind: A1
- Application number: 17/814,968
- Filed: 2022-07-26
- Published: 2023-02-23
- Earliest claimed: 2021-07-29
- Assignees: Washington University
- Inventors: Muhammad Farooq Rai
- Web page: https://patentgrep.com/patent/US20230058864A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61P 19/00: Drugs for skeletal disorders
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/122: Hairpin
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2330/51: Specially adapted vectors
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Among the various aspects of the present disclosure is the provision of methods for treating pathologic calcification or bone formation and methods of inhibiting KIF26B that include administering a therapeutically effective amount of a synthetic nucleic acid against KIF26B. Compositions comprising a small hairpin RNA (shRNA) against KIF26B are also provided.

## Claims

### Claim 1

A method of treating or preventing pathologic calcification or bone formation in a subject comprising administering a therapeutically effective amount of a synthetic nucleic acid against KIF26B.

### Claim 2 (depends on 1)

The method of claim 1, wherein the synthetic nucleic acid comprises:
SEQ ID NO: 1 or a sequence at least about 80% identical to SEQ ID NO: 1;
SEQ ID NO: 2 or a sequence at least about 80% identical to SEQ ID NO: 2; or
any variant thereof having KIF26B inhibiting activity.

### Claim 3 (depends on 1)

The method of claim 1, wherein the synthetic nucleic acid is a small hairpin RNA (shRNA).

### Claim 4 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the synthetic nucleic acid reduces KIF26B mRNA or protein expression.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has or is suspected of having intra-articular ectopic calcification.

### Claim 6 (depends on 5)

The method of claim 5, wherein the intra-articular ectopic calcification is injury-induced ectopic calcification or surgery-induced ectopic calcification.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has or is suspected of having pathologic osteogenesis, heterotopic ossification, pathologic bone formation, osteoarthritis, arthroplasty, or a traumatic injury.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the synthetic nucleic acid:
reduces or prevents osteogenesis;
increases chondrogenesis;
reduces expression of osteogenic marker genes;
increases expression of chondrogenic marker genes; or
reduces expression of Wnt/β-catenin pathway genes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the synthetic nucleic acid reduces cell proliferation, reduces cell viability, or induces cell apoptosis.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cell is a progenitor cell, a stem cell, a cell capable of osteogenic differentiation, or a cell capable of chondrogenic differentiation.

### Claim 11 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the synthetic nucleic acid reduces or prevents ectopic calcification or formation of calcified nodules.

### Claim 12 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the synthetic nucleic acid is administered intra-articularly.

### Claim 13

A method of inhibiting KIF26B expression in a subject in need thereof, the method comprising administrating a therapeutically effective amount of a synthetic nucleic acid against KIF26B.

### Claim 14 (depends on 13)

The method of claim 13, wherein the synthetic nucleic acid is a small hairpin RNA (shRNA).

### Claim 15 (depends on 13)

The method of claim 13, wherein the synthetic nucleic acid comprises:
SEQ ID NO: 1 or a sequence at least about 80% identical to SEQ ID NO: 1;
SEQ ID NO: 2 or a sequence at least about 80% identical to SEQ ID NO: 2; or
any variant thereof having KIF26B inhibiting activity.

### Claim 16 (depends on 13)

The method of claim 13, wherein the subject has or is suspected of having intra-articular ectopic calcification.

### Claim 17 (depends on 13)

The method of claim 13, wherein the therapeutically effective amount of the synthetic nucleic acid is administered intra-articularly.

### Claim 18

A composition comprising a small hairpin RNA (shRNA) against KIF26B, the shRNA comprising:
SEQ ID NO: 1 or a sequence at least about 80% identical to SEQ ID NO: 1;
SEQ ID NO: 2 or a sequence at least about 80% identical to SEQ ID NO: 2; or
any variant thereof having KIF26B inhibiting activity.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the shRNA reduces KIF26B mRNA or protein expression.

### Claim 20 (depends on 18)

The composition of claim 18, further comprising a lentivirus.
